Somewhat Positive Media Coverage Somewhat Unlikely to Affect GenMark Diagnostics (GNMK) Stock Price
Media headlines about GenMark Diagnostics (NASDAQ:GNMK) have been trending somewhat positive this week, according to Accern Sentiment Analysis. The research group rates the sentiment of news coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. GenMark Diagnostics earned a media sentiment score of 0.22 on Accern’s scale. Accern also assigned headlines about the medical equipment provider an impact score of 46.9818226151436 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
Here are some of the news headlines that may have impacted Accern Sentiment Analysis’s analysis:
- Scott Mendel Sells 2,304 Shares of GenMark Diagnostics, Inc (GNMK) Stock (americanbankingnews.com)
- GenMark Diagnostics, Inc (GNMK) SVP Sells $22,646.80 in Stock (americanbankingnews.com)
- Hany Massarany Sells 6,584 Shares of GenMark Diagnostics, Inc (GNMK) Stock (americanbankingnews.com)
- GenMark Diagnostics to Present at Upcoming Investor Conferences (finance.yahoo.com)
- Zacks: Brokerages Expect GenMark Diagnostics, Inc (GNMK) to Post -$0.24 Earnings Per Share (americanbankingnews.com)
Shares of GenMark Diagnostics (GNMK) traded up $0.07 on Thursday, hitting $4.46. The company’s stock had a trading volume of 152,600 shares, compared to its average volume of 470,094. GenMark Diagnostics has a twelve month low of $3.63 and a twelve month high of $13.67. The firm has a market cap of $240.55, a P/E ratio of -3.66 and a beta of 0.78. The company has a quick ratio of 2.77, a current ratio of 2.97 and a debt-to-equity ratio of 0.12.
In other GenMark Diagnostics news, insider Hany Massarany sold 6,584 shares of the firm’s stock in a transaction on Tuesday, February 20th. The stock was sold at an average price of $4.37, for a total value of $28,772.08. Following the completion of the sale, the insider now directly owns 357,190 shares of the company’s stock, valued at approximately $1,560,920.30. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders sold a total of 21,836 shares of company stock valued at $100,151 over the last ninety days. Corporate insiders own 7.50% of the company’s stock.
GenMark Diagnostics Company Profile
GenMark Diagnostics, Inc is a molecular diagnostics company. The Company is focused on developing and commercializing multiplex molecular tests that aid in the diagnosis of complex medical conditions. It develops and commercializes multiplex molecular tests based on its eSensor electrochemical detection technology.
Receive News & Ratings for GenMark Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GenMark Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.